Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37 results about "Lung cancer early detection" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Symptoms and early detection. Lung cancer can be difficult to diagnose because the symptoms can be non-specific and masked by other diseases. If you have one or more of the following symptoms, please see your doctor as soon as possible: persistent cough (lasting longer than 3 weeks) change in cough. coughing up blood.
Electronic nose system for early detection of lung cancer
InactiveCN103018282AHigh sensitivityImprove anti-interference abilityWithdrawing sample devicesMaterial analysis by electric/magnetic meansSensor arrayLung cancer early detection
An electronic nose system for early detection of lung cancer comprises an exhaled air sampling system, a miniature sensor array and a signal preprocessing and pattern recognizing system, wherein the exhaled air sampling system is used for controlling air collection, circulation and rinsing; the miniature sensor array is used for collecting air response signals and converting the air response signals into electrical signals; the signal preprocessing and pattern recognizing system is used for signal processing, conversion and air identification and detection; the exhaled air sampling system comprises an air sampling device and an air chamber air passage unit; the miniature sensor array is encapsulated in the sensor air chamber of the air chamber air passage unit; and the signal preprocessing and pattern recognizing system is arranged outside the sensor air chamber and is connected with the miniature sensor array. The electronic nose system has the advantages of high sensitivity, high response speed, low cost, portability, and easiness in operation; a data base has excellent expandability; and the electronic nose system can be widely applied to early detection of lung cancer, monitoring after recovery and screening of high-risk populations.
Owner:SHANGHAI JIAO TONG UNIV
Mass spectrum model for detecting proteins of lung cancer and construction method thereof
ActiveCN102323246AIncreased sensitivityImprove featuresPreparing sample for investigationDisease diagnosisLung cancer early detectionLung cancer
The invention provides a mass spectrum model for detecting characteristic proteins of a lung cancer. The mass spectrum model comprises peaks with mass charge ratios of 4054 m / z, 2273 m / z, 4091 m / z, 3955 m / z, 3192 m / z, 3884 m / z and 5337 m / z, wherein in the model, proteins expressing the mass charge ratios of 4054 m / z, 2273 m / z, 4091 m / z, 3955 m / z, 3192 m / z, 3884 m / z and 5337 m / z are serum characteristic proteins of the lung cancer; and when the peaks with the mass charge ratios of 4054 m / z, 2273 m / z, 4091 m / z, 3955 m / z and 3192 m / z are expressed in a down regulation manner and the peaks with the mass charge ratios of 3884 m / z and 5337 m / z are expressed in an up regulation manner, a patient is indicated to be a lung cancer patient or a potential patient. The mass spectrum model can be used for early detection and screening for the lung cancer; the method is simple, easy to operate and high in accuracy; and by utilizing the mass spectrum model, a novel idea is provided for early detection and screening for the lung cancer.
Owner:BIOYONG TECH
Methylation marker for early detection of cancer and detection method thereof
ActiveCN105368945AEarly detectionEarly treatmentMicrobiological testing/measurementDNA/RNA fragmentationLung cancer early detectionMicroRNA
The invention relates to a methylation marker for early detection of cancer and a detection method thereof. The methylation marker comprises PCDHGB6, HOXA9, MGMT and microRNA-126 genes. The methylation marker has the advantages of quickness, high throughput, high sensitivity and high specificity when being adopted for combined detection, and the detection method is suitable for early detection of cancer, can be used for late detection of lung cancer and has a good application prospect.
Owner:SHANGHAI INST OF MICROSYSTEM & INFORMATION TECH CHINESE ACAD OF SCI
MicroRNA biological markers for early lung cancer diagnosis and application thereof
ActiveCN103484550AHigh diagnostic valueMicrobiological testing/measurementDNA/RNA fragmentationSerum igeLung cancer early detection
The invention relates to the field of biological detection, particularly to a group of microRNA biological markers for early lung cancer diagnosis and an application thereof. The microRNA biological marker comprises hsa-miR-125a-5p, hsa-miR-193a-5p, hsa-miR-25, hsa-miR-126 and hsa-miR-34a. The serum miRNA biological markers comprising the 5 miRNAs can not only be particularly applied to early lung cancer detection, but also be applied to advanced lung cancer detection.
Owner:SHANGHAI INST OF MICROSYSTEM & INFORMATION TECH CHINESE ACAD OF SCI
Method for lung cancer early detection and prognosis
InactiveUS20110183864A1Accurate predictionNucleotide librariesMicrobiological testing/measurementLung cancer early detectionLung cancer
The present invention provides method for the prognosis or detection of lung cancer, notably for early detection of lung cancer, as well as a kit and a (micro) array suitable for said method.
Owner:UNIV OF COLOGNE +1
Exosome ecDNA biomarker detection reagent for early diagnosis of lung cancer, and use of exosome ecDNA biomarker detection reagent
PendingCN112143814AImprove early detection sensitivityNon-traumaticMicrobiological testing/measurementLung cancer early detectionBiologic marker
The invention relates to an exosome ecDNA biomarker detection reagent for the early diagnosis of lung cancer. The biomarker comprises exosome ecDNA biomarkers C-myc, EGFR and CyclinD1, and is used asa biomarker for predicting early lung cancer. The invention provides and verifies that the advantages of rapidness, no harm, high accuracy and high specificity are achieved when the exosome ecDNA is used as a biomarker expression level for the early diagnosis of lung cancer for the first time, and thereby the detection reagent has important significance for the early diagnosis of lung cancer.
Owner:3D BIOMEDICINE SCI & TECH CO LTD
Prediction model for early diagnosis of lung cancer as well as related products and application thereof
PendingCN113871008AImprove accuracyComponent separationHealth-index calculationLung cancer early detectionArginine
The invention discloses a prediction model for early diagnosis of lung cancer as well as related products and application of the prediction model. The prediction model comprises the following factors: age, gender, arginine, aspartic acid, serine, glutaryl carnitine, isovaleryl carnitine and eicocarbonyl carnitine. The invention further provides a system and a device based on the prediction model and a computer readable storage medium, the early-stage rapid and effective prediction of the lung cancer can be realized, and the method has a very excellent application prospect.
Owner:THE SECOND HOSPITAL OF DALIAN MEDICAL UNIV
Application of GASP-2 detection reagent in preparation of kit for early diagnosis and susceptibility detection of lung cancer
The invention discloses application of a GASP-2 detection reagent in preparation of a kit for early diagnosis and susceptibility detection of lung cancer, and belongs to the field of cancer diagnosis. In serum of a lung cancer patient, the content of GASP-2 is obviously higher than that of normal people. According to the early diagnosis kit for the lung cancer, the lung cancer can be rapidly and accurately diagnosed by detecting the content of GASP-2, and the early diagnosis rate of the lung cancer can be increased, so that the prognosis of a patient with the lung cancer is greatly improved, and the disease burden of the lung cancer is reduced.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Electronic nose system for early detection of lung cancer
InactiveCN103018282BHigh sensitivityImprove anti-interference abilityWithdrawing sample devicesMaterial analysis by electric/magnetic meansHigh risk populationsSensor array
An electronic nose system for early detection of lung cancer comprises an exhaled air sampling system, a miniature sensor array and a signal preprocessing and pattern recognizing system, wherein the exhaled air sampling system is used for controlling air collection, circulation and rinsing; the miniature sensor array is used for collecting air response signals and converting the air response signals into electrical signals; the signal preprocessing and pattern recognizing system is used for signal processing, conversion and air identification and detection; the exhaled air sampling system comprises an air sampling device and an air chamber air passage unit; the miniature sensor array is encapsulated in the sensor air chamber of the air chamber air passage unit; and the signal preprocessing and pattern recognizing system is arranged outside the sensor air chamber and is connected with the miniature sensor array. The electronic nose system has the advantages of high sensitivity, high response speed, low cost, portability, and easiness in operation; a data base has excellent expandability; and the electronic nose system can be widely applied to early detection of lung cancer, monitoring after recovery and screening of high-risk populations.
Owner:SHANGHAI JIAOTONG UNIV
Primer and kit for detecting peripheral blood circulation microRNA related to lung cancer diagnosis and treatment
InactiveCN112980947AImprove accuracyIncreased sensitivityMicrobiological testing/measurementDNA/RNA fragmentationLung cancer early detectionSpecific detection
The invention discloses a group of peripheral blood circulation microRNAs related to diagnosis and treatment of lung cancer and application of the peripheral blood circulation microRNAs. The microRNA is prepared from the following components: hsa-miR-16-5p, hsa-miR-26a-5p, hsa-miR-15b-5p, hsa-miR-21-5p, hsa-miR-191-5p, hsa-miR-195-5p, hsa-miR-223-3p, hsa-miR-92a-3p, hsa-let-7a-5p, hsa-let-7f-5p, hsa-miR-451a and hsa-miR-150-5p. The microRNA specific detection primer and the application of the microRNA specific detection primer in the kit are firstly protected; and a product has a function of diagnosis or auxiliary diagnosis of lung cancer. In addition to protecting a specific primer sequence, a reverse transcription primer, a specific upstream primer and a universal downstream primer are further included; and the microRNA is obviously up-regulated in peripheral blood of the lung cancer, has the advantages of good stability, high specificity and high sensitivity, can be independently used or a combination of more than two microRNAs to assist clinical early diagnosis or prognosis monitoring of the lung cancer, and has important application value.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Detection kit for SDPR gene expression and/or SDPR gene methylation level and application
PendingCN111635941AGood clinical valueGuide medicationMicrobiological testing/measurementMaterial analysisLung cancer early detectionGood prognosis
The invention discloses application of an SDPR gene expression level detection reagent and / or an SDPR gene methylation level detection reagent in preparation of a kit used for diagnosing whether a subject suffers from lung cancer or not, or used for predicting whether the subject has a lung cancer risk or not, or used for judging whether a lung cancer patient is sensitive to chemotherapeutic drugsor not, or used for judging whether the lung cancer patient has good prognosis or not, and belongs to the field of molecular diagnosis. The invention provides a new clinical marker for early diagnosis and treatment of lung cancer, and has huge clinical value.
Owner:THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY
Application of exosome miRNA in preparation of lung cancer early diagnosis kit, and lung cancer early diagnosis detection kit
InactiveCN111172282AEarly diagnosis appliesMicrobiological testing/measurementLung cancer early detectionSquamous Carcinomas
The invention discloses an application of exosome miRNA in the preparation of a lung cancer early diagnosis kit, and a lung cancer early diagnosis detection kit. Specifically, the invention provides ause of an exosome miRNA detection reagent, an application of exosome miRNA as a detection target in the preparation of a lung cancer diagnosis kit, and an application of the reagent for detecting theexosome miRNA expression level in the preparation of a lung cancer early diagnosis kit. The exosome miRNA is adenocarcinoma-specific miR-30a-3p and miR-30e-3p and squamous cell carcinoma-specific miR-10b-5p and miR-15b-5p in non-small cell lung cancer. The real-time fluorescent PCR detection reagent for detecting the miRNA expression level comprises a specific DNA probe. The miRNA and specific DNA probe thereof described in the invention have an auxiliary role in the lung cancer early diagnosis.
Owner:NANJING DRUM TOWER HOSPITAL
A peripheral blood extracellular vesicle microrna biomarker for early diagnosis of lung cancer and its application
ActiveCN111218513BStrong specificityMicrobiological testing/measurementBiostatisticsPulmonary noduleExtracellular vesicle
The invention discloses a peripheral blood extracellular vesicle miRNA biomarker for early diagnosis of lung cancer, characterized in that the peripheral blood extracellular vesicle miRNA biomarker includes hsa-let-7b-3p, hsa-let-7b-3p, hsa-let-7b-3p miR‑125b‑5p, hsa‑miR‑150‑5p, hsa‑miR‑101‑3p, hsa‑miR‑3168. The present invention is based on the peripheral blood of patients with pulmonary nodules detected by LDCT as a research sample, which has higher specificity and is more reliable. The research results are useful for accurately identifying false positive lung cancer patients from patients with pulmonary nodules detected by LDCT. important meaning.
Owner:上海思路迪医学检验所有限公司
A kind of lung cancer marker anti-hmgb3 autoantibody and its application
The invention belongs to the technical field of biomedical detection, and in particular relates to a lung cancer marker anti-HMGB3 autoantibody and its application. The invention discloses a lung cancer marker, and the lung cancer marker is an anti-HMGB3 autoantibody. The present invention also provides the application of the above-mentioned lung cancer markers in the preparation of a lung cancer detection kit. The present invention aims to provide a clinically applicable lung cancer marker with simple operation, low cost, high accuracy and non-invasiveness and a reagent kit for preparing the marker for lung cancer evaluation. The research of the present invention found that the application of ELISA method to detect serum anti-HMGB3 autoantibodies can more accurately distinguish lung cancer patients from normal people, as well as patients with benign lung disease groups (COPD and chronic bronchitis), and can be used for lung cancer early detection. In this context, the convenient, fast and effective marker anti-HMGB3 autoantibody for detecting lung cancer patients and the kit for preparing the marker for lung cancer detection are provided, which can be used for clinical early diagnosis of lung cancer.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Application of ASPH gene in exosome in lung cancer early diagnosis kit
The invention discloses application of ASPH gene in an exosome in a lung cancer early diagnosis kit, and belongs to the technical field of gene detecting. The invention discloses the application of the ASPH gene in the exosome in the lung cancer early diagnosis kit. The kit comprises a primer for detecting the ASPH gene in the exosome and a primer for detecting beta-actin. The application of the ASPH gene in the exosome in the lung cancer early diagnosis kit disclosed by the invention is high in detecting sensitivity and strong in specificity.
Owner:江西惠肽生物科技有限公司 +2
A set of signature proteins used to detect lung cancer
ActiveCN102323246BIncreased sensitivityImprove featuresPreparing sample for investigationDisease diagnosisLung cancer early detectionSerum ige
The present invention provides a mass spectrometry model for detecting characteristic proteins of lung cancer. The peak of z, which is characterized in the model as the protein with mass-to-charge ratios of 4054m / z, 2273m / z, 4091m / z, 3955m / z, 3192m / z, 3884m / z and 5337m / z is the characteristic protein of lung cancer serum, when 4054m / z , 2273m / z, 4091m / z, 3955m / z, 3192m / z peaks down-regulated expression, and 3884m / z, 5337m / z peaks up-regulated expression indicates lung cancer patients or potential patients. The mass spectrometry model of the invention can be used for early detection and screening of lung cancer, the method is simple and easy to operate, and has high accuracy, and provides a new idea for early detection and screening of lung cancer.
Owner:BIOYONG TECH
A kind of lung cancer marker anti-psip1 autoantibody and its application
The invention belongs to the technical field of biomedical detection, and in particular relates to a lung cancer marker anti-PSIP1 autoantibody and its application. The invention discloses a lung cancer marker, and the lung cancer marker is an anti-PSIP1 autoantibody. The present invention also provides the application of the above-mentioned lung cancer markers in the preparation of a lung cancer detection kit. The invention provides a serum biomarker for clinical detection of lung cancer with simple operation, low cost, high accuracy and no trauma. The present invention finds that the application of ELISA method to detect serum anti-PSIP1 autoantibodies can more accurately distinguish lung cancer patients from normal people and patients with benign lung diseases, and can be used for the detection of metastatic lung cancer. In this context, the convenient, fast and effective marker for detecting lung cancer patients and the reagent kit for preparing the marker for lung cancer detection are provided, which can be used for clinical early diagnosis of lung cancer.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Application of miRNA molecule as early lung cancer detection marker
PendingCN114457160AImplement diagnosticsEasy to detectMicrobiological testing/measurementLung cancer early detectionOncology
The invention provides application of a miRNA molecular marker in preparation of an early lung cancer detection reagent, and relates to the technical field of biomedicine. And the miRNA molecular marker comprises miR-99a-5p (micro Ribonucleic Acid). The invention researches the relationship between the miRNA expression level in plasma before the incidence of a new lung cancer case (early lung cancer) and the incidence of lung cancer, and finds that miR-99a-5p has strong identification and prediction capabilities for the early diagnosis of lung cancer, and can be used as a marker for the early screening and / or diagnosis of lung cancer.
Owner:BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
Fluorescence molecular probe for carrying out targeted marking on non-small-cell lung cancer and application thereof
ActiveCN112250733AAchieving clinical translationImprove targetingPeptidesFluorescence/phosphorescenceAmino acidTarget therapy
The invention belongs to the technical field of biological medicine, and provides a fluorescence molecular probe for carrying out targeted marking on the non-small cell lung cancer and application thereof in order to solve the problem of lack of screening on an NCI-H1299 cell line by utilizing a phage display random peptide library at present. The fluorescence molecular probe is a fluorescence marking targeting peptide and is named as FITC-NSP1, and the amino acid sequence of the fluorescence molecular probe is shown as SEQ ID NO. 1. The probe is specifically combined with the non-small-cell lung cancer cell line NCI-H1299, and is applied to detection of the non-small-cell lung cancer in in-vitro human sputum cast-off cells. An experimental basis is provided for molecular diagnosis and targeted therapy of the non-small-cell lung cancer. Screening is carried out in a non-small-cell lung cancer NCI-H1299 cell tumor-bearing mouse body by a Ph.D.-C7CTM cyclic heptapeptide library, the lungcancer targeting peptide NSP1 is successfully obtained, the specificity and targeting of the lung cancer targeting peptide NSP1 are preliminarily verified in vitro and in vivo, and a foundation is laid for research on early diagnosis of the lung cancer.
Owner:山西诺恩精准医疗器械有限责任公司
Preparation method and application of fluorogold nano-cluster coupled Napsin A compound
PendingCN114533904AHas a targeting functionUniform sizeIn-vivo testing preparationsLung cancer early detectionAntiendomysial antibodies
The invention relates to the technical field of high polymer materials, in particular to a preparation method and application of a fluorogold nanocluster coupled Napsin A compound. Comprising the following steps: adding 1-ethyl-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide into a flask of N, N-dimethylformamide, stirring for several minutes, adding 3-mercaptopropionic acid, continuously stirring, and dropwise adding an amino-containing high-molecular long-chain polymer solution under the condition of violent stirring; according to the preparation method and the application of the fluorescent gold nano-cluster coupled Napsin A compound, bright red fluorescent gold nano-clusters are prepared, then 1-ethyl-(3-dimethylaminopropyl) carbodiimide / N-hydroxysuccinimide is utilized for reaction to be coupled with a Napsin A antibody, the compound with a targeting function is obtained, and early diagnosis and intraoperative positioning of lung cancer are carried out.
Owner:JILIN UNIV
A marker for early diagnosis and early warning of metastasis of lung cancer and kit for its preparation
ActiveCN110042162BImprove expression levelReduced expression levelMicrobiological testing/measurementDNA/RNA fragmentationLung cancer early detectionOncology
The invention relates to a marker for early lung cancer diagnosis and prediction of distant metastasis based on platelet LncRNA-STON2 and a kit for its preparation, belonging to the field of medical and health care. The marker is selected from plasma platelet LncRNA-STON2; the kit for preparing the marker includes: a reverse transcription reaction system, a fluorescent quantitative PCR reaction system and an internal reference system; meanwhile, a preparation method of the kit is also provided. The invention proposes for the first time that the expression level of LncRNA‑STON2 in plasma platelets of patients with lung cancer is significantly higher than that of healthy donors. ROC curve analysis shows that the AUC is 0.613, the sensitivity is 61.5%, and the specificity is 59.9%. Compared with healthy donors, the expression of LncRNA-STON2 was significantly increased in early-stage lung cancer patients. ROC curve analysis showed that the AUC was 0.713, the sensitivity was 69.2, and the specificity was 71.9%.
Owner:宋现让
Marker for early diagnosis and metastasis warning of lung cancer and prepared kit thereof
ActiveCN110042162AReduced expression levelImprove expression levelMicrobiological testing/measurementDNA/RNA fragmentationLymphatic SpreadFluorescence
The present invention relates to a marker for early diagnosis and distant metastasis prediction of lung cancer based on platelet LncRNA-STON2 and a prepared kit thereof, and belongs to the fields of medical treatment and public health. The marker is selected from the plasma platelet LncRNA-STON2. The kit prepared from the marker comprises a reverse transcription reaction system, a fluorescence quantitative PCR reaction system and an internal reference system. The present invention also provides a preparation method of the kit. The marker is firstly provided. Compared with healthy donors, an expression level of the LncRNA-STON2 in the plasma platelets of patients with the lung cancer is significantly increased, and a ROC curve analysis shows that AUC is 0.613, sensitivity is 61.5%, and specificity is 59.9%. Compared with the healthy donors, the expression level of the LncRNA-STON2 in patients with early lung cancer is significantly increased, and the ROC curve analysis shows that the AUC is 0.713, the sensitivity is 69.2% and the specificity is 71.9%.
Owner:宋现让
A kit for early diagnosis of lung cancer based on signal amplification of nafion-induced atom transfer radical polymerization
ActiveCN110257519BImprove stabilityGood reproducibilityMicrobiological testing/measurementLung cancer early detectionMagnetic bead
The invention discloses an early diagnosis kit for lung cancer based on signal amplification of atom transfer radical polymerization reaction initiated by Nafion, comprising amino Fe 3 O 4 Magnetic Bead Solution, Sulfo‑SMCC Solution, PNA Solution, ZrClO 2 Solution, Nafion solution, Fluorescein O-acrylate solution, AA solution, CuBr 2 / Me 6 TREN solution, PBS buffer, DMF. The present invention utilizes the polymerization characteristics of Nafion to apply it in the ATRP reaction, as an initiator to improve the polymerization ability of the monomers, a large number of fluorescent monomers are connected and polymerized through the ATRP reaction, and finally, the fluorescence signal intensity determined by a fluorescence spectrometer is related to the target DNA (tDNA). ) concentration was positively correlated, and a detection kit for lung cancer biomarker CYFRA21-1 based on signal amplification of Nafion-induced atom transfer radical polymerization reaction was successfully constructed. The kit of the invention has the characteristics of high sensitivity, high stability, strong anti-interference, low detection limit and the like, and opens up a new way for the clinical detection of lung cancer DNA.
Owner:HENAN UNIV OF CHINESE MEDICINE
A detection method and application of lung cancer gene
ActiveCN106047998BFully reflectAccurately reflectMicrobiological testing/measurementLung cancer early detectionGenes mutation
Owner:深圳海普洛斯医学检验实验室
Application of anti-TIF1 gamma-IgA and anti-TIF1 gamma-IgG as combined diagnosis marker in lung cancer diagnosis
ActiveCN111323590AHigh cure rateImprove 5-year survival rateMaterial analysisLung cancer early detectionAntiendomysial antibodies
The invention provides an application of anti-TIF1 gamma-IgA and anti-TIF1 gamma-IgG as a combined diagnosis marker in early diagnosis of a lung cancer, and belongs to the technical field of medical diagnosis. A condition thata TIF1 gamma protein is abnormally highly expressed in cancer tissues of a patient with an early lung cancer is found for the first time; meanwhile, a strong humoral immune response aiming at TIF1gamma is found to exist in a body of the patient at the early stage of the lung cancer; serum anti-TIF1 gamma-IgA and TIF1 gamma-IgG autoantibodies can be used as markers for early diagnosis of the lung cancer; and combined detection of the anti-TIF1 gamma-IgA and the anti-TIF1 gamma-IgG can obviously improve sensitivity of the early diagnosis of the lung cancer patient on the basis of ensuring specificity, and the application is suitable for being developed into a combined detection kit with a clinical application value. Therefore, the combined detection of the anti-TIF1gamma-IgA and the anti-TIF1 gamma-IgG is helpful for further improving early serological screening quality of the lung cancer patient so that a cure rate and a five-year survival rate of the lung cancer are increased.
Owner:FUJIAN PROVINCIAL HOSPITAL
A kind of lung cancer marker anti-mmp12 autoantibody and its application
The invention belongs to the technical field of biomedical detection, and specifically relates to a lung cancer marker anti-MMP12 autoantibody and its application. The invention discloses a lung cancer marker, and the lung cancer marker is an anti-MMP12 autoantibody. The present invention also provides the application of the above-mentioned lung cancer markers in the preparation of a lung cancer detection kit. The present invention aims to provide a clinically applicable lung cancer marker with simple operation, low cost, high accuracy and non-invasiveness and a reagent kit for preparing the marker for lung cancer evaluation. The present invention finds that the application of ELISA method to detect serum anti-MMP12 autoantibodies can more accurately distinguish lung cancer patients from normal people, as well as patients with benign lung disease groups (COPD and chronic bronchitis), and can be used for the diagnosis of lung cancer. early detection. In this context, the convenient, fast and effective marker for detecting lung cancer patients and the reagent kit for preparing the marker for lung cancer detection are provided, which can be used for clinical early diagnosis of lung cancer.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Microwave breath sensor for early diagnosis of lung cancer and preparation method thereof
ActiveCN109975327BHigh sensitivityImprove consistencyMaterial analysis using microwave meansRespiratory organ evaluationLung cancer early detectionUltraviolet
Owner:王琮
Protein chip and kit for early diagnosis of lung cancer
ActiveCN109470855BAchieve early diagnosisIncreased sensitivityDisease diagnosisAntigenLung cancer early detection
The invention relates to a protein chip and a kit for early diagnosis of lung cancer. The protein chip includes the following ten antigen fragments: MAGE A3 antigen fragment, ANXA1 antigen fragment, CTAG1B antigen fragment, CAGE1 antigen fragment, AP3D1 antigen fragment, CCT8 antigen fragment, CHK antigen fragment, PRKACA antigen fragment, EIF4G1 antigen fragment and MAGE A1 antigen fragment. The protein chip and kit for early diagnosis of lung cancer creatively select antigens that are significantly expressed in the early stage of lung cancer and can cause the immune system to produce related antibodies, and screen the corresponding antigen fragments for combination. Using protein chip technology, the antigen fragments Coated on the surface of a solid support to detect tumor-associated autoantibodies in human serum to achieve early diagnosis of lung cancer, with a high detection positive rate, which can greatly improve the sensitivity and specificity of early lung cancer diagnosis.
Owner:GUANGZHOU BIO BLUE TECH CO LTD
Sample data intelligent processing method and system for early lung cancer diagnosis
PendingCN113611406AAccurate classificationAccurate and effectiveMedical automated diagnosisMedical practises/guidelinesLung cancer early detectionData set
Owner:济宁市第一人民医院
Application of a group of plasma metabolic small molecule markers related to early diagnosis of lung cancer
ActiveCN108414660BIncreased sensitivityImprove featuresComponent separationDiseaseLysophosphatidyl ethanolamine
Owner:CHINA PHARM UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com